Communicators

are winners!

More News

15.05.2024
First Participants Dosed in Next Cohort - Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trial
09.05.2024
Positive Efficacy Data from Murdoch Children’s Research Institute in Pilot Study for Lung Infections
07.05.2024
China Patent Granted for RECCE® Anti-Infectives
16.04.2024
Recce Completes 5,000 RECCE® 327 Doses a Week under Good Manufacturing Practice (GMP)
10.04.2024
Recce Pharmaceuticals Selected by UK Government Innovation Agency to Participate in AMR Mission 2024
08.04.2024
Recce Pharmaceuticals (ASX:RCE, FSE:R9Q) Business Update
15.03.2024
Cohort Dosing Complete Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trial
12.03.2024
Dosing Commenced in Next Cohort - Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trial
08.03.2024
Recce Receives AUD $11.17m R&D Advance
27.02.2024
Independent Safety Committee Approves Expansion of Phase I/II Clinical Trial for Diabetic Foot Infection Treatment